"Global Graves’ Disease (Overactive Thyroid) Market Overview:
Global Graves’ Disease (Overactive Thyroid) Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Graves’ Disease (Overactive Thyroid) Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Graves’ Disease (Overactive Thyroid) involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Graves’ Disease (Overactive Thyroid) Market:
The Graves’ Disease (Overactive Thyroid) Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Graves’ Disease (Overactive Thyroid) Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Graves’ Disease (Overactive Thyroid) Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Graves’ Disease (Overactive Thyroid) market has been segmented into:
Overactive Thyroid
By Application, Graves’ Disease (Overactive Thyroid) market has been segmented into:
Anti-thyroid Drugs
Beta Blockers
Iodine Therapy
Radioactive Iodine Therapy
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Graves’ Disease (Overactive Thyroid) market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Graves’ Disease (Overactive Thyroid) market.
Top Key Players Covered in Graves’ Disease (Overactive Thyroid) market are:
AbbVie Inc.
Pfizer Inc.
RLC LABS
Inc.
Merck KGaA
Eisai Co. Ltd
Novartis AG
Mylan N.V.
Aspen Pharmacare Holdings Ltd
Sanofi
GlaxoSmithKline plc
AstraZeneca
Horizon Therapeutics plc
Alara Pharmaceutical Corporation
Antares Pharma
Inc.
Apitope Technology (Bristol) Ltd.
IONIS Pharmaceuticals
Inc.
Immunovant
Inc.
HanAll Biopharma Co. Ltd
Cara Therapeutics
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Graves’ Disease (Overactive Thyroid) Market by Type
4.1 Graves’ Disease (Overactive Thyroid) Market Snapshot and Growth Engine
4.2 Graves’ Disease (Overactive Thyroid) Market Overview
4.3 Overactive Thyroid
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Overactive Thyroid: Geographic Segmentation Analysis
Chapter 5: Graves’ Disease (Overactive Thyroid) Market by Application
5.1 Graves’ Disease (Overactive Thyroid) Market Snapshot and Growth Engine
5.2 Graves’ Disease (Overactive Thyroid) Market Overview
5.3 Anti-thyroid Drugs
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Anti-thyroid Drugs: Geographic Segmentation Analysis
5.4 Beta Blockers
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Beta Blockers: Geographic Segmentation Analysis
5.5 Iodine Therapy
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Iodine Therapy: Geographic Segmentation Analysis
5.6 Radioactive Iodine Therapy
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Radioactive Iodine Therapy: Geographic Segmentation Analysis
5.7 Others
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Graves’ Disease (Overactive Thyroid) Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ABBVIE INC.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 PFIZER INC.
6.4 RLC LABS
6.5 INC.
6.6 MERCK KGAA
6.7 EISAI CO.
6.8 LTD.
6.9 NOVARTIS AG
6.10 MYLAN N.V.
6.11 ASPEN PHARMACARE HOLDINGS LTD
6.12 SANOFI
6.13 GLAXOSMITHKLINE PLC
6.14 ASTRAZENECA
6.15 HORIZON THERAPEUTICS PLC
6.16 ALARA PHARMACEUTICAL CORPORATION
6.17 ANTARES PHARMA
6.18 INC.
6.19 APITOPE TECHNOLOGY (BRISTOL) LTD.
6.20 IONIS PHARMACEUTICALS
6.21 INC.
6.22 IMMUNOVANT
6.23 INC.
6.24 HANALL BIOPHARMA CO.
6.25 LTD.
6.26 CARA THERAPEUTICS
Chapter 7: Global Graves’ Disease (Overactive Thyroid) Market By Region
7.1 Overview
7.2. North America Graves’ Disease (Overactive Thyroid) Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Overactive Thyroid
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Anti-thyroid Drugs
7.2.5.2 Beta Blockers
7.2.5.3 Iodine Therapy
7.2.5.4 Radioactive Iodine Therapy
7.2.5.5 Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Graves’ Disease (Overactive Thyroid) Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Overactive Thyroid
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Anti-thyroid Drugs
7.3.5.2 Beta Blockers
7.3.5.3 Iodine Therapy
7.3.5.4 Radioactive Iodine Therapy
7.3.5.5 Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Graves’ Disease (Overactive Thyroid) Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Overactive Thyroid
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Anti-thyroid Drugs
7.4.5.2 Beta Blockers
7.4.5.3 Iodine Therapy
7.4.5.4 Radioactive Iodine Therapy
7.4.5.5 Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Graves’ Disease (Overactive Thyroid) Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Overactive Thyroid
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Anti-thyroid Drugs
7.5.5.2 Beta Blockers
7.5.5.3 Iodine Therapy
7.5.5.4 Radioactive Iodine Therapy
7.5.5.5 Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Graves’ Disease (Overactive Thyroid) Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Overactive Thyroid
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Anti-thyroid Drugs
7.6.5.2 Beta Blockers
7.6.5.3 Iodine Therapy
7.6.5.4 Radioactive Iodine Therapy
7.6.5.5 Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Graves’ Disease (Overactive Thyroid) Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Overactive Thyroid
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Anti-thyroid Drugs
7.7.5.2 Beta Blockers
7.7.5.3 Iodine Therapy
7.7.5.4 Radioactive Iodine Therapy
7.7.5.5 Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Graves’ Disease (Overactive Thyroid) Scope:
|
Report Data
|
Graves’ Disease (Overactive Thyroid) Market
|
|
Graves’ Disease (Overactive Thyroid) Market Size in 2025
|
USD XX million
|
|
Graves’ Disease (Overactive Thyroid) CAGR 2025 - 2032
|
XX%
|
|
Graves’ Disease (Overactive Thyroid) Base Year
|
2024
|
|
Graves’ Disease (Overactive Thyroid) Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
AbbVie Inc., Pfizer Inc., RLC LABS, Inc., Merck KGaA, Eisai Co., Ltd., Novartis AG, Mylan N.V., Aspen Pharmacare Holdings Ltd, Sanofi, GlaxoSmithKline plc, AstraZeneca, Horizon Therapeutics plc, Alara Pharmaceutical Corporation, Antares Pharma, Inc., Apitope Technology (Bristol) Ltd., IONIS Pharmaceuticals, Inc., Immunovant, Inc., HanAll Biopharma Co., Ltd., Cara Therapeutics.
|
|
Key Segments
|
By Type
Overactive Thyroid
By Applications
Anti-thyroid Drugs
Beta Blockers
Iodine Therapy
Radioactive Iodine Therapy
Others
|
